Abstract:INTRODUCTION AND OBJECTIVES: AKR1C3, as a crucial steroidogenic enzyme, facilitated intratumoral androgen biosynthesis and androgen receptor (AR) reactivation in the development of castration-resistant prostate cancer. Also, amount of data have shown that AKR1C3 expression was significantly elevated in clinical metastatic prostate cancer (PCa) specimens, indicating an alternative role of AKR1C3 in PCa metastasis. Epithelial-mesenchymal transition (EMT) has been recognized to play pivotal roles in promoting carcinoma invasion and metastasis; however, the roles of AKR1C3 in EMT and PCa metastasis have not been fully elucidated. METHODS: C4-2, 22RV1-T and PC-3 cells with higher AKR1C3 expression were selected and treated with several specific AKR1C3 shRNAs or small molecule inhibitor, and the cell migration and invasion abilities were detected by wound healing assay and Transwell assay. The expression of EMT markers (i.e., E-cadherin and vimentin) and the related transcription factors (i.e., Snail, Slug, ZEB1 and Twist1) was examined by Western blot or quantitative PCR assays, and the phosphorylation of AKT or ERK was detected by Western blot. Also, the expression of vimentin, ZEB1 and p-ERK (T202/Y204) was detected by immunohistochemical staining in PC-3 xenograft tissues after AKR1C3 inhibitor treatment. The correlation between AKR1C3 and EMT markers (including EMT-related transcription factors) expression in clinical specimens from tissue microarray or TCGA database was analyzed. RESULTS: AKR1C3 was overexpressed in more aggressive PCa cell lines regardless of the AR status. Knock-down of AKR1C3 expression or inhibition of AKR1C3 activity could significantly suppressed cell migration and invasion abilities in vitro. Also, knock-down of AKR1C3 expression or inhibition of AKR1C3 activity could increase E-cadherin expression but decrease vimentin expression, in which the phosphorylation of ERK and the transcription factor ZEB1 expression were specifically downregulated. In consistency, inhibition of AKR1C3 activity by inhibitor treatment could decrease the expression of vimentin, ZEB1 and p-ERK (T202/Y204) in xenograft tissues in vivo. Moreover, there was a significant correlation between AKR1C3 and EMT markers (i.e., E-cadherin, vimentin and ZEB1) in human PCa specimens. CONCLUSIONS: AKR1C3 is a novel EMT regulator in PCa metastasis through activation of MAPK/ERK signaling and upregulation of ZEB1 expression.

AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling.

MP62-19 AKR1C3 OVEREXPRESSION IN PROSTATE CANCER PROMOTES EPITHELIAL-MESENCHYMAL TRANSITION AND METASTASIS VIA ACTIVATION OF MAPK/ERK SIGNALING AND UPREGULATION OF ZEB1

CRABP2 Promotes Cell Migration and Invasion by Activating PI3K/AKT and MAPK Signalling Pathways Via Upregulating LAMB3 in Prostate Cancer

Akr1c3 Overexpression May Serve As A Promising Biomarker for Prostate Cancer Progression

Acyl-CoA Synthetase Long-Chain 3 Regulates AKT Phosphorylation and the Functional Activity of Human Prostate Cancer Cells

RON and C-Met Facilitate Metastasis Through the ERK Signaling Pathway in Prostate Cancer Cells.

The AKR1C3/AR-V7 Complex Maintains CRPC Tumour Growth by Repressing B4GALT1 Expression.

AKR1C2 Promotes Metastasis and Regulates the Molecular Features of Luminal Androgen Receptor Subtype in Triple Negative Breast Cancer Cells

AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer.

AKR1C2 Acts As a Targetable Oncogene in Esophageal Squamous Cell Carcinoma Via Activating PI3K/AKT Signaling Pathway.

The androgen receptor plays a suppressive role in epithelial- mesenchymal transition of human prostate cancer stem progenitor cells

AKR1C3 Promotes Progression and Mediates Therapeutic Resistance by Inducing Epithelial-Mesenchymal Transition and Angiogenesis in Small Cell Lung Cancer

Prkar2b Promotes Prostate Cancer Metastasis By Activating Wnt/-Catenin And Inducing Epithelial-Mesenchymal Transition

AKR1C3 mediates gastric cancer cell invasion and metastasis via the AKT and JNK/p-NF-κB signaling pathways

RAB3D, upregulated by aryl hydrocarbon receptor (AhR), promotes the progression of prostate cancer by activating the PI3K/AKT signaling pathway

CRABP2 promotes cell migration and invasion by activating PI3K/AKT and MAPK signaling pathways via up-regulating LAMB3 in prostate cancer

Estrogen receptor α-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer

CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and αvβ3 integrin clustering

AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies

Therapeutic potential of targeting AKR1C2 in the treatment of prostate cancer

Cxcr6 Induces Prostate Cancer Progression By The Akt/Mammalian Target Of Rapamycin Signaling Pathway